Literature DB >> 12025886

Effect of vinorelbine monotherapy in taxane-treated patients with advanced non-small-cell lung cancer.

Junya Miyata1, Takahiro Sano, Hiroyasu Bando.   

Abstract

Taxane-based chemotherapy now plays an important role in the first-line treatment on patients with advanced non-small-cell lung cancer (NSCLC). Recent attention has been focused on the treatment of patients with NSCLC who failed to respond to taxane-based chemotherapy. In the present article, we report the effect of single-agent vinorelbine (VNR) in 10 patients with NSCLC previously treated with taxanes. An antitumor effect was observed in five patients, resulting in a response rate of 50.0% (5/10). The absence of vinca alkaloid pretreatment was an important factor in the clinical response in these patients. Further study is warranted to investigate the clinical efficacy of VNR monotherapy in taxane-resistant NSCLC patients.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12025886     DOI： 10.1385/MO:19:1:11

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  11 in total

1.  Phase II study of alternating doses of vinorelbine in combination with cisplatin for non-small cell lung cancer (NSCLC): a disappointing experience.

Authors:  V Westeel; P Jacoulet; J L Breton; G Garnier; M Mercier; A Depierre
Journal:  Lung Cancer       Date:  1996-12       Impact factor: 5.705

Review 2.  Single-agent vinorelbine in the treatment of non-small cell lung cancer.

Authors:  A J Wozniak
Journal:  Semin Oncol       Date:  1999-10       Impact factor: 4.929

3.  Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients: a minnie pearl cancer research network phase II trial.

Authors:  J D Hainsworth; H A Burris; S Litchy; J B Erland; J K Hon; J E Brierre; F A Greco
Journal:  Cancer       Date:  2000-03-15       Impact factor: 6.860

4.  Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations.

Authors:  M Monzó; R Rosell; J J Sánchez; J S Lee; A O'Brate; J L González-Larriba; V Alberola; J C Lorenzo; L Núñez; J Y Ro; C Martín
Journal:  J Clin Oncol       Date:  1999-06       Impact factor: 44.544

5.  Concurrent administration of vinorelbine with human recombinant granulocyte-macrocyte stimulating factor.

Authors:  A J Weiss; R D Lackman
Journal:  Int J Oncol       Date:  2001-03       Impact factor: 5.650

6.  A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Japan Vinorelbine Lung Cancer Study Group.

Authors:  K Furuse; K Kubota; M Kawahara; M Ogawara; E Kinuwaki; M Motomiya; Y Nishiwaki; H Niitani; A Sakuma
Journal:  Lung Cancer       Date:  1994-12       Impact factor: 5.705

7.  A phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer.

Authors:  A Depierre; E Lemarie; G Dabouis; G Garnier; P Jacoulet; J C Dalphin
Journal:  Am J Clin Oncol       Date:  1991-04       Impact factor: 2.339

8.  Multicenter Phase II trial of intermediate dose cisplatin and vinorelbine in inoperable non-small cell lung cancer patients.

Authors:  S Bretti; A Berruti; G Gorzegno; P La Ciura; E Pazè; A Celano; G Grecchi; D Perroni; C Bumma; L Dogliotti
Journal:  Lung Cancer       Date:  1996-06       Impact factor: 5.705

9.  Failure of vinorelbine to produce responses in pretreated non-small cell lung cancer patients.

Authors:  P Pronzato; M Landucci; F Vaira; A Vigani; G Bertelli
Journal:  Anticancer Res       Date:  1994 May-Jun       Impact factor: 2.480

10.  Carboplatin and vinorelbine in advanced non-small-cell lung cancer.

Authors:  P Pronzato; E Ghio; P L Losardo; M Landucci; F Vaira; A Vigani
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.